GeoVax Labs Inc
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marb… Read more
GeoVax Labs Inc (GOVX) - Total Liabilities
Latest total liabilities as of September 2025: $1.82 Million USD
Based on the latest financial reports, GeoVax Labs Inc (GOVX) has total liabilities worth $1.82 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
GeoVax Labs Inc - Total Liabilities Trend (1996–2024)
This chart illustrates how GeoVax Labs Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
GeoVax Labs Inc Competitors by Total Liabilities
The table below lists competitors of GeoVax Labs Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Abpro Holdings, Inc.
NYSE:ABP
|
USA | $17.30 Million |
|
AVI Japan Opportunity Trust PLC
LSE:AJOT
|
UK | £15.54 Million |
|
TV Thunder Public Company Limited
BK:TVT
|
Thailand | ฿38.95 Million |
|
Intersport Polska S.A.
WAR:IPO
|
Poland | zł210.92 Million |
|
Commcenter S.A.
MC:CMM
|
Spain | €25.75 Million |
|
bioAffinity Technologies Inc. Warrant
NASDAQ:BIAFW
|
USA | $2.64 Million |
Liability Composition Analysis (1996–2024)
This chart breaks down GeoVax Labs Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GeoVax Labs Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GeoVax Labs Inc (1996–2024)
The table below shows the annual total liabilities of GeoVax Labs Inc from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.11 Million | -11.72% |
| 2023-12-31 | $3.52 Million | -25.87% |
| 2022-12-31 | $4.75 Million | -36.14% |
| 2021-12-31 | $7.43 Million | +801.21% |
| 2020-12-31 | $825.00K | -59.63% |
| 2019-12-31 | $2.04 Million | +22.80% |
| 2018-12-31 | $1.66 Million | +105.10% |
| 2017-12-31 | $811.29K | +119.36% |
| 2016-12-31 | $369.85K | +191.24% |
| 2015-12-31 | $126.99K | -32.10% |
| 2014-12-31 | $187.02K | -40.12% |
| 2013-12-31 | $312.35K | -4.49% |
| 2012-12-31 | $327.04K | -65.27% |
| 2011-12-31 | $941.53K | +80.51% |
| 2010-12-31 | $521.61K | -8.71% |
| 2009-12-31 | $571.37K | +64.93% |
| 2008-12-31 | $346.42K | -42.12% |
| 2007-12-31 | $598.54K | +209.94% |
| 2006-12-31 | $193.11K | -96.67% |
| 2005-12-31 | $5.79 Million | +16.68% |
| 2004-12-31 | $4.97 Million | +24.46% |
| 2003-12-31 | $3.99 Million | +294.83% |
| 2002-12-31 | $1.01 Million | -45.92% |
| 2001-12-31 | $1.87 Million | +192.00% |
| 2000-12-31 | $639.91K | -77.31% |
| 1999-12-31 | $2.82 Million | -26.46% |
| 1998-12-31 | $3.83 Million | +140.62% |
| 1997-12-31 | $1.59 Million | +414.11% |
| 1996-12-31 | $309.96K | -- |